Pacira Biosciences Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 19, 2023 / 02:15PM GMT
Serge Belanger - Needham & Company, LLC - Analyst

Hi. Good morning. I'm Serge Belanger, one of the senior healthcare analysts at Needham. I want to welcome you to our 22nd Annual Healthcare Conference. For our next session. We have the Pacira team with us, so the CEO, David Stack; as well as the CFO, Charles Reinhart. So welcome, gentlemen, and I'll hand it over to David to just to give us a brief overview of the company.

[We'll get] the questions, and for those listening in on the portal, you do have the options to submit questions. I think it's at the bottom of your screen. So, David?

David Stack - Pacira BioSciences, Inc. - CEO & Chairman

Good morning, Serge, and thanks for the opportunity. Through Q1, I think we're -- the easiest thing to say, I guess, is that we're on plan. The marketplace remains relatively soft for soft-tissue procedures. In the hard-tissue procedure in the orthopedic space, we would echo what folks would have heard from many of the device companies that knees and hips are growing. The rest of [orthopedics] looks a lot

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot